Won Hwee, PA
Surgical · Tualatin, ORNPI 1083967020
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Astellas Pharma US Inc at 27.1% of the total. 2025 is the largest year on record at $831, more than ten times the $80 reported in 2021.
Across 92 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$562
- AbbVie$132
- Bayer$128
- Pfizer$126
- Accord Healthcare, Inc.$110
- Sumitomo Pharma America, Inc.$105
- plus $906 from 23 others
What the payments were for
- Food & beverage$1,95795%
- Education$1135%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 25 | $562 |
| AbbVie | 6 | $132 |
| Bayer | 7 | $128 |
| Pfizer | 5 | $126 |
| Accord Healthcare, Inc. | 6 | $110 |
| Sumitomo Pharma America, Inc. | 3 | $105 |
| AstraZeneca | 4 | $88 |
| Endo USA, Inc. | 3 | $73 |
| Tolmar, Inc. | 3 | $68 |
| Progenics Pharmaceuticals, Inc. | 3 | $68 |
| Teleflex LLC | 2 | $59 |
| Johnson & Johnson(2 entities) | 2 | $56 |
| Olympus America Inc. | 2 | $55 |
| Merck | 2 | $52 |
| Convatec Inc. | 1 | $45 |
| Endo Pharmaceuticals Inc. | 2 | $41 |
| Halozyme Inc | 2 | $40 |
| Boston Scientific | 2 | $40 |
| 180 Medical, Inc. | 1 | $28 |
| Myriad Genetic Laboratories, Inc. | 2 | $27 |
| Antares Pharma, Inc. | 1 | $25 |
| Gilead | 1 | $24 |
| Myovant Sciences Inc. | 1 | $24 |
| Urogen Pharma, Inc. | 1 | $21 |
| Telix Pharmaceuticals | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $19 |
| Coloplast | 1 | $16 |
| Immunitybio, Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $4 |
How this compares
$2,070 in reported general payments places this provider in the 85th percentile of 229 surgical providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 11 | $148,066 |
| MyrbetriqMirabegron | 107 | $61,288 |
| GemtesaVibegron | 70 | $60,692 |
| Abiraterone Acetate | 13 | $19,981 |
| Testosterone | 22 | $8,597 |
| Methenamine Hippurate | 49 | $5,587 |
| Tamsulosin Hcl | 318 | $4,939 |
| Trospium Chloride | 74 | $3,820 |
| Estradiol | 55 | $3,161 |
| Testosterone Cypionate | 53 | $2,727 |
| NitrofurantoinNitrofurantoin Macrocrystal | 43 | $2,377 |
| Finasteride | 172 | $2,373 |
| Cephalexin | 95 | $1,214 |
| Solifenacin Succinate | 55 | $1,074 |
| Silodosin | 12 | $1,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $562 | $209,353118 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $105 | $60,69270 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 229 surgical providers in Oregon.
Other surgical in Tualatin
- James BerkingMedford$15K
- Amanda ShinpaughLake Oswego$9K
- Justin ThibeaultPortland$6K
- Benjamin BairdRoseburg$6K
- Kelly ChristnerSpringfield$5K
- Shea DeklotzPortland$5K
- Colleen PhillipsPortland$4K
- Erin KhourySalem$4K
- Amber TravisSpringfield$4K
- Michael PurvisPortland$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.